title: Galectin-3: a novel protein in cerebellar hemangioblastoma.
abstract: Hemangioblastoma (HB), a rare neoplasm of uncertain histogenesis, is characterized histologically by the presence of vacuolated; lipid-containing cells 'stromal cells' and a well developed, fine capillary network. Stromal cells are the neoplastic component of this tumor. Five-um sections were stained using streptavidin- biotin immunoperoxidase and immunofluorescent techniques. The stromal cells were uniformly "HIF-1α, Galectin-3, VEGF, VEGFR, WT-1, and bcl2," positive. Endothelial cells but not stromal cells were uniformly immunoreactive to CD31. Co-localization of HIF-1α with galectin-3 and VEGF as well as galectin-3 with VEGF in stromal cells is confirmed by immunofluorescent technique. In conclusion, the development of HB is multi-factorial and the expression of galectin-3 correlates with the expression of HIF-1α and VEGF. Galectin-3 can be used as a marker for the diagnosis of HB as well as it can be a valuable candidate for future targeting immunotherapy.
authors: Department of Pathology, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, PO box 17666, UAE. suhaila@uaeu.ac.ae
authors: Suhail
authors: S
authors: Al-Salam
authors: Mohammed
authors: M
authors: Al-Salam
authors: Moueid
authors: M
authors: Al Ashari
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D001798:Blood Proteins; D002528:Cerebellar Neoplasms / Q000378:metabolism*; D005455:Fluorescent Antibody Technique; D037502:Galectin 3 / Q000032:analysis / Q000096:biosynthesis*; D037161:Galectins; D018325:Hemangioblastoma / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry
chemical_list: D014408:Biomarkers, Tumor; D001798:Blood Proteins; D037502:Galectin 3; D037161:Galectins; C428445:LGALS3 protein, human
keywords: CNS neoplasms; HIF; galectin-3; hemangioblastoma
references: Cell Death Differ. 2008 Apr;15(4):621-7
references: 18259201
references: Blood. 2006 Apr 1;107(7):2705-12
references: 16304044
references: Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4
references: 7539918
references: FASEB J. 2001 May;15(7):1312-4
references: 11344124
references: J Biol Chem. 1994 Aug 19;269(33):20807-10
references: 8063692
references: Acta Neuropathol. 2007 Aug;114(2):97-109
references: 17618441
references: J Biol Chem. 2011 Dec 23;286(51):43634-43643
references: 22030397
references: Pathol Int. 2005 Jul;55(7):377-85
references: 15982211
references: J Appl Physiol (1985). 2000 Apr;88(4):1474-80
references: 10749844
references: J Biol Chem. 2009 Jun 19;284(25):16767-16775
references: 19386601
references: Cancer Res. 2006 Jun 15;66(12):6264-70
references: 16778202
references: Mol Pharm. 2004 Mar-Apr;1(2):156-65
references: 15832512
references: J Biol Chem. 2001 Mar 23;276(12):9519-25
references: 11120745
references: PLoS One. 2010 Jul 27;5(7):e11772
references: 20668552
references: Cancer Res. 2000 Mar 15;60(6):1541-5
references: 10749120
references: Nature. 1999 May 20;399(6733):271-5
references: 10353251
references: J Exp Med. 2010 Aug 30;207(9):1981-93
references: 20713592
references: Nature. 1995 Aug 10;376(6540):517-9
references: 7543654
references: FEBS Lett. 2002 Feb 13;512(1-3):157-62
references: 11852072
references: Science. 2001 Apr 20;292(5516):464-8
references: 11292862
references: Am J Pathol. 2000 Mar;156(3):899-909
references: 10702407
references: J Pathol. 2005 Jul;206(3):291-304
references: 15906272
references: Int J Exp Pathol. 2007 Oct;88(5):311-24
references: 17877533
references: J Bone Miner Res. 2007 Dec;22(12):1851-61
references: 17592963
references: J Biol Chem. 2002 Nov 8;277(45):42919-25
references: 12200433
references: Cancer Res. 1999 Aug 15;59(16):3915-8
references: 10463582